Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David H M Steffin

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 22, 2019
Epigenetic Inhibition Puts Target Antigen in the Crosshairs of CAR T CellsDavid H M Steffin, Helen E Heslop
Advances in Pediatrics|June 25, 2019
Gene Therapy: Current Applications and Future PossibilitiesDavid H M Steffin, Emily M Hsieh, Rayne H Rouce
Research Square|April 25, 2024
Eighteen-year survival after GD2-directed Chimeric Antigen Receptor-Modified Immune Effector Cell Treatment for NeuroblastomaLi Che-Hsing, Sandhya Sharma, Andras A Heczey, et al.
Nature Medicine|February 17, 2025
Long-term outcomes of GD2-directed CAR-T cell therapy in patients with neuroblastomaChe-Hsing Li, Sandhya Sharma, Andras A Heczey, et al.
Blood|March 24, 2022
Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECsDavid H M Steffin, Ibrahim N Muhsen, LaQuisa C Hill, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 22, 2019
Epigenetic Inhibition Puts Target Antigen in the Crosshairs of CAR T CellsDavid H M Steffin, Helen E Heslop
Advances in Pediatrics|June 25, 2019
Gene Therapy: Current Applications and Future PossibilitiesDavid H M Steffin, Emily M Hsieh, Rayne H Rouce
Research Square|April 25, 2024
Eighteen-year survival after GD2-directed Chimeric Antigen Receptor-Modified Immune Effector Cell Treatment for NeuroblastomaLi Che-Hsing, Sandhya Sharma, Andras A Heczey, et al.
Nature Medicine|February 17, 2025
Long-term outcomes of GD2-directed CAR-T cell therapy in patients with neuroblastomaChe-Hsing Li, Sandhya Sharma, Andras A Heczey, et al.
Blood|March 24, 2022
Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECsDavid H M Steffin, Ibrahim N Muhsen, LaQuisa C Hill, et al.
Pageof 1